Speech Date

2025/08/25

Theme

Announcement pursuant to §25 I subpara. 4 of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies

Fact Date

2025-08-25

Describe

1.Date of occurrence of the event: 2025/08/25
2.For the company for whom the endorsements/guarantees were made(1)Company name(2)Its relationship with the Company providing endorsements/guarantees(3)The ceiling on the endorsements/guarantees (thousand NTD)(4)The original amount of endorsements/guarantees (thousand NTD)(5)the amount of the current additional endorsements/guarantees (thousand NTD)(6)The amount of endorsements/guarantees as of the dateof occurrence (thousand NTD)(7)The actual loaned amount of the company for whom endorsements/guarantees were made (thousand NTD)(8)The reason for the current additional endorsements/guarantees:
(1)Company name: Royal Seal Holding Co., Ltd.
(2)Its relationship with the Company providing endorsements/guarantees:
The company providing endorsements/guarantees: Cowealth Medical Holding Co., Ltd.
The company's subsidiaries directly and indirectly hold more than 50% of the shares
(3)The ceiling on the endorsements/guarantees (thousand NTD): 4,916,803
(4)The original amount of endorsements/guarantees (thousand NTD): 405,173
(5)the amount of the current additional endorsements/guarantees (thousand NTD): 250,000
(6)The amount of endorsements/guarantees as of the date of occurrence(thousand NTD): 655,173
(7)The actual loaned amount of the company for whom endorsements/guarantees were made (thousand NTD): 234,663
(8)The reason for the current additional endorsements/guarantees: Renewing the bank credit limit and signing a new contract
3.For collaterals provided by the company for whom the endorsements/guarantees were made, the (1)Content(2)Value (thousand NTD):
(1)Content: None
(2)Value (thousand NTD): 0
4.For the latest financial statements of the company for whom the endorsements/guarantees were made, the (1)Capital (thousand NTD)(2)Cumulative gains/losses (thousand NTD):
(1)Capital (thousand NTD): 770,451
(2)Cumulative gains/losses (thousand NTD): -158,428
5.For termination of endorsement/guarantee obligations, the (1)Condition(2)Date:
(1)Condition: Maturity of bank financing
(2)Date: Maturity of bank financing
6.The total amount of the ceiling on endorsements/guarantees (thousand NTD): 12,292,006
7.The total amount of endorsements/guarantees as of the date of occurrence (thousand NTD): 1,897,923
8.The amount of endorsements/guarantees provided by A as a percentage of the public company's net worth on the latest financial report as of the date of occurrence: 0.77
9.The aggregate amount of long-term investments, endorsements/guarantees, and monetary loans extended to others as a percentage of the public company's net worth on the latest financial statements: 1.58
10.Any other matters that need to be specified:
Some of the bank lines were not yet expired, there is a situation where the endorsement and guarantee lines were double-calculated.

Speech Date

2025/08/25

Theme

Announcement pursuant to §22 I subpara. 3 of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies

Fact Date

2025-08-25

Describe

1.Date of occurrence of the event: 2025/08/25
2.Funding recipient:
(1)Name: Cowealth Holding Co., Ltd.
(2)Relationship with lender:
Lender: COWEALTH HOLDING CO.,LTD.
100% direct and indirect subsidiaries of the parent company
(3)Lending limit (thousand NTD): 266,272
(4)Starting outstanding balance (thousand NTD): 91,135
(5)New loan (thousand NTD): 91,135
(6)Is it part of a scheduled allocation or revolving limit for the same recipient that the chairman is authorized by the board of directors to allocate: Yes
(7)Outstanding balance (thousand NTD) up to the date of occurrence: 182,270
(8)Reason for new loan (thousand NTD): Working capital
3.For collaterals provided by the loan recipient, the(1)Content(2)Value (thousand NTD):
(1)Content: None
(2)Value (thousand NTD): 0
4.For the latest financial reports of the loan recipient, the (1)Capital (thousand NTD) (2)Cumulative gains/losses (thousand NTD):
(1)Capital (thousand NTD): 751,205
(2)Cumulative gains/losses (thousand NTD): 1,302,193
5.Method of calculation of interest: Not lower than the average interest rate on short-term debt from financial institutions at the time of lending.
6.For repayment, the(1)Condition(2)Date:
(1)Condition: None
(2)Date: One year starting on the first payment date
7.The amount of monetary loans extended to others as of the date of occurrence (thousand NTD): 1,976,428
8.The total amount of monetary loans extended to others as a percentage of the public company's net worth on the latest financial statements as of the date of occurrence: 0.80
9.Sources of funds for the company to extend monetary loans to others: Subsidiary's own funds
10.Any other matters that need to be specified: None

Speech Date

2025/08/25

Theme

Announcement pursuant to §22 I subpara. 3 of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies

Fact Date

2025-08-25

Describe

1.Date of occurrence of the event: 2025/08/25
2.Funding recipient:
(1)Name: Royal Seal Holding Co., Limited.
(2)Relationship with lender:
Lender: Cowealth Medical China Co., Ltd.
100% direct and indirect subsidiaries of the parent company
(3)Lending limit (thousand NTD): 1,810,888
(4)Starting outstanding balance (thousand NTD): 82,850
(5)New loan (thousand NTD): 165,700
(6)Is it part of a scheduled allocation or revolving limit for the same recipient that the chairman is authorized by the board of directors to allocate: Yes
(7)Outstanding balance (thousand NTD) up to the date of occurrence: 248,550
(8)Reason for new loan (thousand NTD): Working capital
3.For collaterals provided by the loan recipient, the (1)Content(2)Value (thousand NTD):
(1)Content: None
(2)Value (thousand NTD): 0
4.For the latest financial reports of the loan recipient, the (1)Capital (thousand NTD) (2)Cumulative gains/losses (thousand NTD):
(1)Capital (thousand NTD): 770,451
(2)Cumulative gains/losses (thousand NTD): -158,428
5.Method of calculation of interest: Not lower than the average interest rate on short-term debt from financial institutions at the time of lending.
6.For repayment, the(1)Condition(2)Date:
(1)Condition: None
(2)Date: One year starting on the first payment date
7.The amount of monetary loans extended to others as of the date of occurrence (thousand NTD): 1,976,428
8.The total amount of monetary loans extended to others as a percentage of the public company's net worth on the latest financial statements as of the date of occurrence: 0.80
9.Sources of funds for the company to extend monetary loans to others: Parent company and Financial Institutions
10.Any other matters that need to be specified:
The original lending limit was reduced from RMB 200 million to RMB 20 million by the Board of Directors and will expire on November 26, 2025.
This is a new application for a lending limit.

Speech Date

2025/08/25

Theme

Announcement pursuant to §22 I subpara. 1 of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies

Fact Date

2025-08-25

Describe

1.Date of occurrence of the event: 2025/08/25
2.The public company or its subsidiaries for which the amount of monetary loans extended to others reaches 20 percent or more of their net worth on the latest financial statements:
(1)Name of funding recipient: Cowealth Medical Shandong Co., Ltd.
(2)Relationship with lender:
Lender: Cowealth Medical China Co., Ltd.
100% direct and indirect subsidiaries of the parent company
(3)Lending limit (thousand NTD): 1,810,888
(4)Outstanding balance (thousand NTD) up to the date of occurrence: 41,425
(5)Reason for lending up to the date of occurrence: Working capital

3.The total amount of monetary loans extended to others as of the date of occurrence: 1,976,428
4.The total amount of monetary loans extended to others as a percentage of the public company's net worth on the latest financial statements as of the date of occurrence: 0.80
5.Sources of funds for the company to extend monetary loans to others: Parent company and Financial Institutions
6.Any other matters that need to be specified: None

Speech Date

2025/08/25

Theme

Announcement on Behalf of Subsidiary CMC regarding the proposed investment in BenQ BM Holding Cayman Corp.

Fact Date

2025-08-25

Describe

1.Name and nature of the underlying assets: BenQ BM Holding Cayman Corp. shares
2.Date of occurrence of the event: 2025/08/25~2025/08/25
3.Volume, unit price, and total monetary amount of the transaction:
(1) Transaction quantity and Unit price: N/A. The final number of trading units shall be determined by the actual transaction amount.
(2) Total transaction amount: Not to exceed US$8,000,000.
4.Trading counterparty and its relationship to the Company: BenQ BM Holding Cayman Corp. ；NA
5.Where the trading counterparty is a related party, announcement shall also be made of the reason for choosing the related party as trading counterparty and the identity of the previous owner, its relationship with the Company and the trading counterparty, and the previous date and monetary value of transfer: NA
6.Where an owner of the underlying assets within the past five years has been an related party of the Company, the announcement shall also include the date and price of acquisition and disposal by the related party, and its relationship to the Company at the time of the transaction: NA
7.Matters related to the current disposal of creditors' rights: NA
8.Profit or loss from the disposal: NA
9.Terms of delivery or payment, restrictive covenants in the contract, and other important terms and conditions: CORNERSTONE INVESTMENT AGREEMENT；NA
10.The manner in which the current transaction was decided, the reference basis for the decision on price, and the decision-making unit:
(1) Pricing reference basis: Subscription for common shares of BenQ BM Holding Cayman Corp.
(2) Decision-making unit: Board of Directors
11.Net worth per share of the Company’s underlying securities acquired or disposed of: NA
12.Cumulative no.of shares held, their monetary value, shareholding percentage, and status of any restriction of rights, as of the present moment:
(1) Cumulative holding amount: Not to exceed US$8,000,000.
(2) Shareholding ratio: NA. The final shareholding ratio will be determined by the actual amount of funds raised.
(3) Restrictions on rights: None
13.Ratio of securities investment to the total assets and shareholder's equity of the parent company on the latest financial statements, and the operating capital on the latest financial statements, as of the present moment:
(1) Percentage of total assets: 3.57%
(2) Percentage of equity attributable to owners of parent: 9.64%
(3) Working capital: 3,445,089 (thousand NTD)
14.Broker and broker's fee: None
15.Concrete purpose or use of the acquisition or disposal: Financial investment
16.Whether the directors expressed any objection to the current transaction: None
17.Whether the counterparty of the current transaction is a related party: No
18.Date of the Board of Directors' resolution: 2025/08/25
19.Date of ratification by supervisors or approval by the Audit Committee: 2025/08/25
20.Whether the CPA issued an opinion on the unreasonableness regarding the current transaction: NA
21.Name of the CPA firm: NA
22.Name of the CPA: NA
23.License no.of the CPA: NA
24.Whether the transaction involved in change of business model: No
25.Details on change of business model: NA
26.Details on transactions with the counterparty for the past year and the expected coming year: NA
27.Source of funds: Working capital
28.Any other matters that need to be specified: No

Speech Date

2025/08/25

Theme

Announcement Regarding the Dissolution and Liquidation of the Company's Subsidiary, Cowealth Holding Co., Ltd.

Fact Date

2025-08-25

Describe

1.Date of occurrence of the event: 2025/08/25
2.Company name: Cowealth Holding Co., Ltd.
3.Relationship to the Company (please enter "head office" or "subsidiaries"): Subsidiaries
4.Reciprocal shareholding ratios: 100% indirectly-owned
5.Cause of occurrence:
In order to streamline the group's structure and operational management, the Board of Directors has resolved to proceed with the dissolution and liquidation of the company's 100% indirectly-owned subsidiary, Cowealth Holding Co., Ltd.
The Chairman of the company or a designated representative is authorized to handle all related matters.
6.Countermeasures: None
7.Any other matters that need to be specified: This dissolution and liquidation will not affect the company's business and operations

Speech Date

2025/08/25

Theme

Announcement Regarding the Dissolution and Liquidation of the Company's Subsidiaries, Cowealth Investment Co., Ltd. and Jie-Li Investment Co., Ltd.

Fact Date

2025-08-25

Describe

1.Date of occurrence of the event: 2025/08/25
2.Company name:
(1)Cowealth Investment Co., Ltd.
(2)Jie-Li Investment Co., Ltd.
3.Relationship to the Company (please enter "head office" or "subsidiaries"): Subsidiaries
4.Reciprocal shareholding ratios: 100% directly-owned
5.Cause of occurrence:
In order to streamline the group's structure and operational management, the Board of Directors has resolved to proceed with the dissolution and liquidation of the company's wholly-owned subsidiaries, Cowealth Investment Co., Ltd. and Jie-Li Investment Co., Ltd.
The Chairman of the company or a designated representative is hereby authorized to handle all related matters.
6.Countermeasures:None
7.Any other matters that need to be specified: This dissolution and liquidation will not affect the company's business and operations

Speech Date

2025/08/25

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. for the resolutions by the Board of Directors

Fact Date

2025-08-25

Describe

1.Date of occurrence of the event: 2025/08/25
2.Company name: Cowealth Medical China Co., Ltd(CMC)
3.Relationship to the Company (please enter "head office" or "subsidiaries"): Subsidiaries
4.Reciprocal shareholding ratios: Hold 55.00% shares
5.Cause of occurrence: Announcement on behalf of important subsidiary CMC for the resolutions by the Board of Directors
(1) Resolutions Regarding the Proposal for the Company's 2025 Semi-Annual Report and its Summary
(2) Resolutions Regarding the Proposal for the Special Report on the Storage and Actual Use of the Raised Funds for the 2025 Semi-Annual Period
6.Countermeasures: None
7.Any other matters that need to be specified:
For details of the above announcement, please refer to the disclosure website of Shanghai Stock Exchange: http://www.sse.com.cn/

Speech Date

2025/08/25

Theme

Announcement of the Board of Directors approved the change of Financial Officer and Accounting Officer

Fact Date

2025-08-25

Describe

1.Type of personnel changed: Financial Officer and Accounting Officer
2.Date of occurrence of the change: 2025/08/25
3.Name, title, and resume of the previous position holder:
(1) Financial Officer: Juan, Yu-Ting / Accounting Manager (acting)
(2) Accounting Officer: Juan, Yu-Ting / Accounting Manager (acting)
4.Name, title, and resume of the new position holder:
(1) Financial Officer: Juan, Yu-Ting / Accounting Manager
(2) Accounting Officer: Juan, Yu-Ting / Accounting Manager
5.Type of change (please enter: "resignation", "position adjustment", "dismissal", "retirement", "death" or "new replacement"): New replacement
6.Reason for the change: New replacement
7.Effective date: 2025/08/25
8.Any other matters that need to be specified:
The newly appointed individuals were approved for appointment by the Board of Directors on August 25, 2025.

Speech Date

2025/08/25

Theme

Announcement of the Board of Directors approved the consolidated financial statements for the second quarter of 2025

Fact Date

2025-08-25

Describe

1.Date of the board of directors submitted or approved:2025/08/25
2.Date of the audit committee approved:2025/08/25
3.Start and end dates of financial reports or unaudited financial information of the reporting period:2025/01/01~2025/06/30
4.Operating revenue accumulated from 1/1 to end of the period(thousand NTD):1,612,821
5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):245,095
6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):(80,954)
7.Profit (loss) before tax accumulated from 1/1 to end of the period(thousand NTD):(87,415)
8.Profit (loss) accumulated from 1/1 to end of the period(thousand NTD):(76,444)
9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):(54,005)
10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):(0.69)
11.Total assets end of the period (thousand NTD):6,639,330
12.Total liabilities end of the period (thousand NTD):2,140,378
13.Equity attributable to owners of parent end of the period (thousand NTD):2,458,402
14.Any other matters that need to be specified:None

Speech Date

2025/08/15

Theme

The Company's Unaudited Accounts Receivable Balance and Collection Amount for July 2025

Fact Date

2025-08-15

Describe

1.Date of occurrence of the event:2025/08/15
2.Company name:Cowealth Medical Holding Co., Ltd. and its subsidiaries
3.Relationship to the Company (please enter ”head office” or
”subsidiaries”):head office and its subsidiaries (”the Company”)
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:In accordance with the regulations
set forth in the Letter No.1140200951 issued by OTC on June 4, 2025.
6.Countermeasures:To proceed in accordance with the regulations specified
in the letter.
7.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 9
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):
(1) According to the explanation in Letter No. 1140200951 issued
by the Taipei Exchange:
As of the end of July, the Company's accounts receivable balance
is NT$3,523,302 thousand (including overdue accounts receivable
of NT$1,365,972 thousand and non-overdue accounts receivable
of NT$2,157,330 thousand), accounting for 52.21% of total assets
and 454.92% of Common Stock. The amount recieved in July
was NT$239,822 thousand.
(2) Progress on Collection of Overdue Accounts Receivable and
Implementation of Security Measures:
The Company's primary customers are public hospitals, and the overdue
accounts receivable are mainly due to delays in hospitals receiving
reimbursements from medical insurance authorities. For customers with
ongoing repayments, the Company has assigned dedicated personnel to
conduct weekly collection efforts and track payment progress. Sales
personnel have also been assigned to actively communicate with these
customers. The Company has increased collection amounts through the
use of supply chain notes. In addition to entering into debt repayment
agreements with customers that stipulate regular repayments, the
Company also controls their sales credit limit to manage accounts
receivable risks. Furthermore, for customers with difficult collections,
the Company has initiated lawsuits and, as appropriate, filed for asset
preservation procedures.
Furthermore, the Company has made progress through active
communication this period with its third-largest customer with overdue
accounts receivable. It is expected that the overdue payments will be
resolved in the second half of 2025. The Company will continue to
closely monitor and follow up on the matter.

Speech Date

2025/08/15

Theme

Announcement for the Board of Directors meeting date of 2025Q2 Consolidated Financial Report

Fact Date

2025-08-15

Describe

1.Date of a notice of the board of directors meeting is issued:2025/08/15
2.Expected date of the board of directors meeting is convened:2025/08/25
3.Expected year and quarter of the financial reports
or the annual self-assessed financial information
submitted to the board of directors or approved by
the board of directors:2025Q2 consolidated financial report
4.Any other matters that need to be specified:None

Speech Date

2025/07/16

Theme

Announcement of the change of Financial Officer, Accounting Officer

Fact Date

2025-07-16

Describe

1.Type of personnel changed (please enter:
spokesperson, acting spokesperson, important
personnel (CEO, COO, CMO, CSO, etc.), financial
officer, accounting officer, corporate governance
officer, chief information security officer,research
and development officer, internal audit officer, or
designated and non-designated representatives):
Financial Officer and Accounting Officer
2.Date of occurrence of the change:2025/07/16
3.Name, title, and resume of the previous position holder:
(1) Financial Officer: Tian, Jing / Finance Director
(2) Accounting Officer: Tian, Jing / Finance Director
4.Name, title, and resume of the new position holder:
(1) Financial Officer: Juan, Yu-Ting / Accounting Manager (acting)
(2) Accounting Officer: Juan, Yu-Ting / Accounting Manager (acting)
5.Type of change (please enter: ”resignation”,
”position adjustment”, ”dismissal”, ”retirement”,
”death” or ”new replacement”):Resignation
6.Reason for the change:Personal career planning
7.Effective date:2025/07/16
8.Any other matters that need to be specified:
The positions of Financial Officer and Accounting Officer are all
temporary. The official appointees will be announced after the
formal appointment by the Board of Directors.

Speech Date

2025/07/15

Theme

The Company's Unaudited Accounts Receivable Balance and Collection Amount for Jun 2025

Fact Date

2025-07-15

Describe

1.Date of occurrence of the event:2025/07/15
2.Company name:Cowealth Medical Holding Co., Ltd. and its subsidiaries
3.Relationship to the Company (please enter ”head office” or
”subsidiaries”):head office and its subsidiaries (”the Company”)
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:In accordance with the regulations
set forth in the Letter No.1140200951 issued by OTC on June 4, 2025.
6.Countermeasures:To proceed in accordance with the regulations specified
in the letter.
7.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 9
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):
(1) According to the explanation in Letter No. 1140200951 issued
by the Taipei Exchange:
As of the end of Jun, the Company's accounts receivable balance
is NT$3,406,225 thousand (including overdue accounts receivable
of NT$1,287,489 thousand and non-overdue accounts receivable
of NT$2,118,736 thousand), accounting for 50.44% of total assets
and 439.80% of Common Stock. The amount recieved in May
was NT$250,722 thousand.
(2) Progress on Collection of Overdue Accounts Receivable and
Implementation of Security Measures:
The Company's primary customers are public hospitals. The overdue
accounts receivable are mainly due to delays in hospitals receiving
reimbursements from medical insurance authorities. The Company has
assigned dedicated personnel to conduct weekly collection efforts and
track payment progress, and has increased collection amounts through
the use of supply chain notes. Apart from entering into debt repayment
agreements with customers stipulating regular repayments, the Company
also controls their sales credit limit to manage accounts receivable risks.
As of this month, the accounts receivable balance has decreased compared
to last month, and its proportion of total assets and equity has also
simultaneously declined. This indicates that the Company's collection
mechanism has gradually shown effectiveness, and the overall recovery
situation is steadily improving.

Speech Date

2025/07/14

Theme

Announcement on Behalf of Subsidiary CMC Regarding the Q2 2025 Earnings Forecast

Fact Date

2025-07-14

Describe

1.Date of occurrence of the event:2025/07/14
2.Company name:Cowealth Medical China Co., Ltd (CMC)
3.Relationship to the Company (please enter ”head office” or
”subsidiaries”):Subsidiaries
4.Reciprocal shareholding ratios:Hold 55.00% shares
5.Cause of occurrence:The subsidiary will announce its Q2 2025
performance forecast in accordance with the Rules Governing the
Listing of Stocks on Shanghai Stock Exchange.
6.Countermeasures:NA.
7.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 9
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):
Cowealth Medical China Co., Ltd. Q2 2025 Performance Forecast is as follows:
(1) Net Profit Attributable to Shareholders of the Listed Company:
RMB -9.0 million to -6.3 million
(2) Net Profit After Deducting Non-Recurring Gains and Losses:
RMB -8.72 million to -6.02 million
(3) Explanation of Performance Change:
(3-1) In the first half of 2025, the company's product procurement prices
for hospital clients were lowered due to changes in the domestic
macroeconomic environment and healthcare policies like centralized
procurement and price reductions. Order volumes also fell short of the
same period last year, leading to a simultaneous decline in the
company's sales revenue and gross profit.
(3-2) To address market and business changes, the company has
actively adjusted its business layout and development strategy. We're
continuously concentrating and expanding resource investment into the
iterative research and development and production of our ”ACME”
proprietary products. We're also expanding our market development
team and enhancing high value-added services for hospital clients. Our
goal is to explore new, sustainable business avenues beyond the
centralized procurement segment.
(3-3) Influenced by external factors, the appreciation of the New Taiwan
Dollar resulted in foreign exchange losses compared to the same period
last year, which also negatively impacted the company's net profit.
(3-4) The company has implemented various expense control measures,
but in the short term, the reduction in our selling, general, and
administrative (SG&A) expenses was less than the decrease in revenue.
This led to a decline in operating performance compared to the same period
last year.
(4) Other Important Notes:
The above financial data is self-compiled by our company and is
unaudited by a CPA firm. The final figures will be subject to the official
release in our company's 2025 semi-annual report.

Speech Date

2025/07/03

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. for the ex-dividend record date and the date of cash dividend distribution

Fact Date

2025-07-03

Describe

1.Date of the resolution by the board of directors or shareholders' meeting
or decision by the Company:2025/06/25
2.Type of ex-rights or ex-dividend (please enter: “Ex-rights”,
”Ex-dividend”, or ”Ex-rights and dividend”):Ex-dividend
3.Type and monetary amount of dividend distribution:
Cash Dividends RMB$51,746,842.29 (tax included)
4.Ex-rights (ex-dividend) trading date:NA
5.Last date before book closure:NA
6.Book closure starting date:NA
7.Book closure ending date:NA
8.Ex-rights (ex-dividend) record date:2025/07/14
9.Deadline for applying the conversion of the debt voucher:NA
10.The closure period for the conversion of the debt voucher will
start from the date:NA
11.The closure period for the conversion of the debt voucher
will end on the date:NA
12.Payment date of cash dividend distribution:2025/07/14
13.Any other matters that need to be specified:NA
This profit distribution plan was approved at the 2024 annual shareholders'
meeting on 2025/6/25. The shareholder list as of the close of trading on
2025/7/11 is used as the basis for dividend distribution, the cash dividend
distribution date is 2025/7/14.The profit distribution plan
is based on a share capital of 398,052,633 shares,
cash dividend is RMB$0.13 per share(tax included),
total of RMB$51,746,842.29 (tax included).

Speech Date

2025/06/27

Theme

Announcement on Behalf of Important Subsidiary CMC Regarding the Cumulative Disposal of Certificates of Financial Products Reaching the Disclosure Threshold

Fact Date

2025-06-27

Describe

1.Name and nature of the underlying assets (if preferred shares,
the terms and conditions of issuance shall also be indicated,
e.g., dividend yield, etc.):Structured Deposit of Bank of Hangzhou (China)
2.Date of occurrence of the event:2025/03/12~2025/06/27
3.Volume, unit price, and total monetary amount of the transaction:
This purchase is for RMB. 10,000,000
The total cumulative purchase is RMB 35,000,000
4.Trading counterparty and its relationship to the Company
(if the trading counterparty is a natural person and
furthermore is not a related party of the Company, the name
of the trading counterparty is not required to be disclosed):
Bank of Hangzhou (China) (Non-related party)
5.Where the trading counterparty is a related party,
announcement shall also be made of the reason for choosing
the related party as trading counterparty and the
identity of the previous owner, its relationship with
the Company and the trading counterparty, and the previous
date and monetary value of transfer:None
6.Where an owner of the underlying assets within the past
five years has been an related party of the Company, the
announcement shall also include the date and price of
acquisition and disposal by the related party, and its
relationship to the Company at the time of the transaction:None
7.Matters related to the current disposal of creditors’
rights (including types of collaterals of the disposed
creditor’s rights; if creditor’s rights over a related
party, announcement shall be made of the name of the
related party and the book amount of the creditor's
rights, currently being disposed of, over such related
party:None
8.Profit or loss from the disposal (not applicable in
cases of acquisition of securities) (where originally
deferred, the status of recognition shall be listed and
explained):Disposal gain of RMB 80,219.18
9.Terms of delivery or payment (including payment period
and monetary value), restrictive covenants in the contract,
and other important terms and conditions:One-time payment
10.The manner in which the current transaction was
decided, the reference basis for the decision on price,
and the decision-making unit:
Expected Annualized Return of the Product as Announced by the Bank.
Processed according to the company’s approval authority.
11.Net worth per share of the Company’s underlying securities
acquired or disposed of:None
12.Cumulative no.of shares held (including the current
transaction), their monetary value, shareholding percentage,
and status of any restriction of rights (e.g., pledges),
as of the present moment:
None
13.Ratio of securities investment (including the current
transaction) to the total assets and shareholder’s equity
of the parent company on the latest financial statements,
and the operating capital on the latest financial statements,
as of the present moment:
Percentage of total assets: 2.19%
Percentage of equity of parent company: 5.51%
Working capital: NTD 4,113,951 thousand
14.Broker and broker’s fee:None
15.Concrete purpose or use of the acquisition or disposal:
RMB Structured Deposit
16.Whether the directors expressed any objection to the current
transaction:None
17.Whether the counterparty of the current transaction
is a related party:None
18.Date of the Board of Directors’ resolution:NA
19.Date of ratification by supervisors or approval by
the Audit Committee:NA
20.Whether the CPA issued an opinion on the unreasonableness
regarding the current transaction:None
21.Name of the CPA firm:None
22.Name of the CPA:None
23.License no.of the CPA:None
24.Whether the transaction involved in change of business model:None
25.Details on change of business model:None
26.Details on transactions with the counterparty for the past
year and the expected coming year:Plan according to the overall financial
condition of the group, following the procedures for asset acquisition
or disposal.
27.Source of funds:Operating funds
28.Any other matters that need to be specified:None

Speech Date

2025/06/27

Theme

Announcement on Behalf of Important Subsidiary CMC Regarding the Cumulative Acquisition of Certificates of Financial Products Reaching the Disclosure Threshold

Fact Date

2025-06-27

Describe

1.Name and nature of the underlying assets (if preferred shares,
the terms and conditions of issuance shall also be indicated,
e.g., dividend yield, etc.):Structured Deposit of Bank of Hangzhou (China)
2.Date of occurrence of the event:2025/04/28~2025/06/27
3.Volume, unit price, and total monetary amount of the transaction:
This purchase is for RMB. 20,000,000
The total cumulative purchase is RMB 36,000,000
4.Trading counterparty and its relationship to the Company
(if the trading counterparty is a natural person and
furthermore is not a related party of the Company, the name
of the trading counterparty is not required to be disclosed):
Bank of Hangzhou (China) (Non-related party)
5.Where the trading counterparty is a related party,
announcement shall also be made of the reason for choosing
the related party as trading counterparty and the
identity of the previous owner, its relationship with
the Company and the trading counterparty, and the previous
date and monetary value of transfer:None
6.Where an owner of the underlying assets within the past
five years has been an related party of the Company, the
announcement shall also include the date and price of
acquisition and disposal by the related party, and its
relationship to the Company at the time of the transaction:None
7.Matters related to the current disposal of creditors’
rights (including types of collaterals of the disposed
creditor’s rights; if creditor’s rights over a related
party, announcement shall be made of the name of the
related party and the book amount of the creditor's
rights, currently being disposed of, over such related
party:None
8.Profit or loss from the disposal (not applicable in
cases of acquisition of securities) (where originally
deferred, the status of recognition shall be listed and
explained):None
9.Terms of delivery or payment (including payment period
and monetary value), restrictive covenants in the contract,
and other important terms and conditions:One-time payment
10.The manner in which the current transaction was
decided, the reference basis for the decision on price,
and the decision-making unit:
Expected Annualized Return of the Product as Announced by the Bank.
Processed according to the company’s approval authority.
11.Net worth per share of the Company’s underlying securities
acquired or disposed of:None
12.Cumulative no.of shares held (including the current
transaction), their monetary value, shareholding percentage,
and status of any restriction of rights (e.g., pledges),
as of the present moment:
Cumulative holding amount:RMB 36,000,000
Restricted rights: RMB 0
13.Ratio of securities investment (including the current
transaction) to the total assets and shareholder’s equity
of the parent company on the latest financial statements,
and the operating capital on the latest financial statements,
as of the present moment:
Percentage of total assets: 2.19%
Percentage of equity of parent company: 5.55%
Working capital: NTD 4,113,951 thousand
14.Broker and broker’s fee:None
15.Concrete purpose or use of the acquisition or disposal:
RMB Structured Deposit
16.Whether the directors expressed any objection to the current
transaction:None
17.Whether the counterparty of the current transaction
is a related party:None
18.Date of the Board of Directors’ resolution:NA
19.Date of ratification by supervisors or approval by
the Audit Committee:NA
20.Whether the CPA issued an opinion on the unreasonableness
regarding the current transaction:None
21.Name of the CPA firm:None
22.Name of the CPA:None
23.License no.of the CPA:None
24.Whether the transaction involved in change of business model:None
25.Details on change of business model:None
26.Details on transactions with the counterparty for the past
year and the expected coming year:Plan according to the overall financial
condition of the group, following the procedures for asset acquisition
or disposal.
27.Source of funds:Operating funds
28.Any other matters that need to be specified:None

Speech Date

2025/06/25

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. for the resolutions by the Board of Directors

Fact Date

2025-06-25

Describe

1.Date of occurrence of the event:2025/06/25
2.Company name:Cowealth Medical China Co., Ltd(CMC)
3.Relationship to the Company (please enter ”head office” or
”subsidiaries”):subsidiaries
4.Reciprocal shareholding ratios:hold 55.00% shares
5.Cause of occurrence:Announcement on behalf of important subsidiary CMC
for the resolutions by the Board of Directors
1、Resolutions Regarding the Proposal for the Election of the Chairman of
the Third Session of the Board of Directors
2、Resolutions Regarding the Proposal for the Establishment of Specialized
Committees of the Board of Directors
3、Resolutions Regarding the Proposal for the Appointment of the General
Manager
4、Resolutions Regarding the Proposal for the Appointment of the Deputy
General Manager and the Chief Financial Officer
5、Resolutions Regarding the Proposal for the Appointment of the Secretary
to the Board of Directors and the Securities Affairs Representative
6.Countermeasures:None
7.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 9
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):For details of the above announcement,
please refer to the disclosure website of Shanghai Stock Exchange:
http://www.sse.com.cn/

Speech Date

2025/06/25

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. for the resolutions of 2024 annual general shareholders’ meeting

Fact Date

2025-06-25

Describe

1.Date of the shareholders' meeting:2025/06/25
2.Important resolutions I.Profit distribution/deficit compensation:
of the Supervisory Board, Change of Business Scope, Adjustment of the
Distribution Plan for the Year 2024”
3.Important resolutions II.Amendments of the company charter:
Approval of the ”Resolutions Regarding the Proposal on the Cancellation
of the Supervisory Board, Change of Business Scope, Adjustment of the
Board Composition, Amendment to the Articles of Association, and
Authorization to Handle Industrial and Commercial Registration Changes”
4.Important resolutions III.Business report and financial statements:
Approval of the ”Resolutions Regarding the 2024 Financial Statements
Report of the Company”
5.Important resolutions IV.Election for directors and supervisors:
5.1 Approval of the ”Resolutions Regarding the Proposal on the Election of
Non-Independent Directors of the Third Session of the Board of Directors”
5.2 Approval of the ” Resolutions Regarding the Proposal on the Election of
Independent Directors of the Third Session of the Board of Directors”
6.Important resolutions V.Other matters:
(1)Approval of the ”Resolutions Regarding the 2024 Board of Directors'
Work Report of the Company”
(2)Approval of the ”Resolutions Regarding the 2024 Independent Directors'
Performance Report of the Company”
(3)Approval of the ”Resolutions Regarding the 2024 Supervisory Board's
Work Report of the Company”
(4)Approval of the ”Resolutions Regarding the 2024 Annual Report and
its Summary of the Company”
(5)Approval of the “Resolutions Regarding the Proposal for the Company's
Director Remuneration Plan for the Year 2025
(6)Approval of the ”Resolutions Regarding the Plan for the Guarantee Quota
for the Year 2025 of the Company”
(7)Approval of the “Resolutions Regarding the Proposal for the Company's
Application for Credit Line from Banks and Other Financial Institutions”
(8)Approval of the “Resolutions Regarding the Proposal for the Completion
and Termination of Certain Fundraising Projects and the Use of
Remaining Funds for Permanent Supplementation of Working Capital”
(9)Approval of the “Resolutions Regarding the Proposal to Amend Certain
Company Rules and Regulations”
(9.1)Proposal on the Amendment to the ”Rules of Procedure for
Shareholders’ Meetings”
(9.2)Proposal on the Amendment to the ”Rules of Procedure for Board of
Directors’ Meetings”
(9.3)Proposal on the Amendment to the ”Working Rules for Independent
Directors”
(9.4)Proposal on the Amendment to the ”Administrative Measures for the Use
of Proceeds”
(9.5)Proposal on the Amendment to the ”Detailed Rules for the
Implementation of Cumulative Voting System”
(9.6)Proposal on the Amendment to the ”Compensation Management System
for Directors and Supervisors”
(9.7)Proposal on the Amendment to the ”Administrative Measures for External
Guarantees”
(9.8)Proposal on the Amendment to the ”Administrative Measures for
Related-Party Transactions”
(9.9)Proposal on the Amendment to the ”Rules of Procedure for the Audit
Committee of the Board of Directors”
(9.10)Proposal on the Amendment to the ”Rules of Procedure for the
Remuneration and Appraisal Committee of the Board of Directors”
(9.11)Proposal on the Amendment to the ”Rules of Procedure for the Strategy
and ESG Committee of the Board of Directors”
(9.12)Proposal on the Amendment to the ”Rules of Procedure for the
Nomination Committee of the Board of Directors”
(9.13)Proposal on the Amendment to the ”Working Rules for the Annual Report
Duties of Independent Directors”
(9.14)Proposal on the Amendment to the ”Detailed Rules for the Duties of the
General Manager”
(9.15)Proposal on the Amendment to the ”Detailed Rules for the Duties of the
Board Secretary”
(9.16)Proposal on the Amendment to the ”Administrative Measures for Investor
Relations Management”
(9.17)Proposal on the Amendment to the ”Administrative Measures for
Information Disclosure”
(9.18)Proposal on the Amendment to the ”Internal Reporting System for
Material Information”
(9.19)Proposal on the Amendment to the ”Insider Information Registration and
Management System”
(9.20)Proposal on the Amendment to the ”Administrative Measures for the
Shareholding and Changes Thereof of Directors, Supervisors, and
Senior Management of the Company”
(9.21)Proposal on the Amendment to the ”System for Preventing the
Misappropriation of Company Funds by Controlling Shareholders and
Related Parties”
(9.22)Proposal on the Amendment to the ”Accountability System for Major
Errors in Annual Report Information Disclosure”
(9.23)Proposal on the Amendment to the ”Administrative Measures for
Deferred and Exempted Information Disclosure”
(9.24)Proposal on the Amendment to the ”Internal Audit System”
7.Any other matters that need to be specified:
For details of the above announcement, please refer to the disclosure website
of Shanghai Stock Exchange: http://www.sse.com.cn/

Speech Date

2025/06/16

Theme

The Company's Unaudited Accounts Receivable Balance and Collection Amount for May 2025

Fact Date

2025-06-16

Describe

1.Date of occurrence of the event:2025/06/16
2.Company name:Cowealth Medical Holding Co., Ltd. and its subsidiaries
3.Relationship to the Company (please enter ”head office” or
”subsidiaries”):head office and its subsidiaries (”the Company”)
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:In accordance with the regulations
set forth in the Letter No.1140200951 issued by OTC on June 4, 2025.
6.Countermeasures:To proceed in accordance with the regulations specified
in the letter.
7.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 9
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):
(1) According to the explanation in Letter No. 1140200951 issued
by the Taipei Exchange:
As of the end of May, the Company's accounts receivable balance
is NT$3,521,881 thousand (including overdue accounts receivable
of NT$1,279,719 thousand and non-overdue accounts receivable
of NT$2,242,162 thousand), accounting for 50.89% of total assets
and 454.73% of Common Stock. The amount recieved in May
was NT$252,521 thousand.
(2) Progress on Collection of Overdue Accounts Receivable and
Implementation of Security Measures:
The Company's primary customers are public hospitals. The overdue accounts
receivable are mainly due to delays in hospitals receiving reimbursements
from medical insurance authorities. For customers with ongoing payments,
the Company has assigned dedicated personnel to conduct weekly collection
efforts and track payment progress. In addition, sales representatives
actively communicate with customers and assist in increasing payment amounts
through the use of supply chain notes.Apart from entering into debt repayment
agreements stipulating regular repayments, the company also controls the
sales volume to such customers to manage accounts receivable risks. For
customers with significant payment difficulties, the Company has initiated
legal proceedings and, where appropriate, implemented asset preservation
measures through the courts.

Speech Date

2025/06/10

Theme

Announcement about resignation of the director

Fact Date

2025-06-10

Describe

1.Date of occurrence of the change:2025/06/10
2.Elected or changed position (Please enter institutional director,
institutional supervisor, independent director, natural-person director or
natural-person supervisor):natural-person director
3.Title, name and nationality of the previous position holder:
natural-person director, Po-Chien Hu, ROC
4.Resume of the previous position holder:
natural-person director, Po-Chien Hu,
Former Sales Director of Cowealth Medical China Co., Ltd.
5.Title, name and nationality of the new position holder:NA
6.Resume of the new position holder:NA
7.Circumstances of change (Please enter “resignation”, “dismissal”,
“term expired”, “death” or “new appointment”):resignation
8.Reason for the change:personal reason
9.Number of shares held by the new position holder when elected:NA
10.Original term (from __________ to __________):2023/05/24~2026/05/23
11.Effective date of the new appointment:NA
12.Turnover rate of directors of the same term:1/9
13.Turnover rate of independent directors of the same term:NA
14.Turnover rate of supervisors of the same term:NA
15.Change in one-third or more of directors (Please enter “Yes” or
“No”):No
16.Directors with a registered household address in ROC.does not
exceed 1/2 of the existing directors after the change (Please enter
“Yes”or ”No”,if ”yes”, please indicate the countermeasures):No
17.Only less than 2 independent directors with a registered
household address in ROC.after the change (Please enter ”Yes”
or “No”,if ”yes”, please indicate the countermeasures):No
18.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 6
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):
Effective date of resignation is 2024/05/15.

Speech Date

2025/06/10

Theme

Announcement about resignation of the director

Fact Date

2025-06-10

Describe

1.Date of occurrence of the change:2025/06/10
2.Elected or changed position (Please enter institutional director,
institutional supervisor, independent director, natural-person director or
natural-person supervisor):natural-person director
3.Title, name and nationality of the previous position holder:
natural-person director, Po-Chien Hu, ROC
4.Resume of the previous position holder:
natural-person director, Po-Chien Hu,
Former Sales Director of Cowealth Medical China Co., Ltd.
5.Title, name and nationality of the new position holder:NA
6.Resume of the new position holder:NA
7.Circumstances of change (Please enter “resignation”, “dismissal”,
“term expired”, “death” or “new appointment”):resignation
8.Reason for the change:personal reason
9.Number of shares held by the new position holder when elected:NA
10.Original term (from __________ to __________):2023/05/24~2026/05/23
11.Effective date of the new appointment:NA
12.Turnover rate of directors of the same term:1/9
13.Turnover rate of independent directors of the same term:NA
14.Turnover rate of supervisors of the same term:NA
15.Change in one-third or more of directors (Please enter “Yes” or
“No”):No
16.Directors with a registered household address in ROC.does not
exceed 1/2 of the existing directors after the change (Please enter
“Yes”or ”No”,if ”yes”, please indicate the countermeasures):No
17.Only less than 2 independent directors with a registered
household address in ROC.after the change (Please enter ”Yes”
or “No”,if ”yes”, please indicate the countermeasures):No
18.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 6
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):
Effective date of resignation is 2025/06/10.

Speech Date

2025/06/04

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. for the resolutions by the Board of Directors

Fact Date

2025-06-04

Describe

1.Date of occurrence of the event:2025/06/04
2.Company name:Cowealth Medical China Co., Ltd(CMC)
3.Relationship to the Company (please enter ”head office” or
”subsidiaries”):subsidiaries
4.Reciprocal shareholding ratios:hold 55.00% shares
5.Cause of occurrence:Announcement on behalf of important subsidiary CMC
for the resolutions by the Board of Directors
1、Resolutions Regarding the proposal to cancel the Supervisory Board,
Amend the Business Scope, Adjust the Number of Directors and Independent
Directors, Revise the Articles of Incorporation, and Authorize the
Registration of Business Changes
2、Resolutions Regarding the Proposal to Amend Certain Company Rules
and Regulations
3、Resolutions Regarding the Proposal for the Nomination of Candidates
for Non-Independent Directors of the Third Board of Directors
4、Resolutions Regarding the Proposal for the Nomination of Candidates
for Independent Directors of the Third Board of Directors
5、Resolutions Regarding the Proposal to Amend the Profit Distribution
Plan for the Year 2024
6、Resolutions Regarding the Proposal to Convene the Annual Shareholders'
Meeting of the Company for the Year 2024
6.Countermeasures:None
7.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 9
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):For details of the above announcement,
please refer to the disclosure website of Shanghai Stock Exchange:
http://www.sse.com.cn/

Speech Date

2025/06/04

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. for the resolution by the Board of Directors to change distribute dividends

Fact Date

2025-06-04

Describe

1.Date of the board of directors resolution:2025/06/04
2.Type and monetary amount of dividend distribution:
Cash Dividends RMB$51,746,842.29(tax included)
3.Any other matters that need to be specified:
For details of the above announcement, please refer to the disclosure website
of Shanghai Stock Exchange: http://www.sse.com.cn/

Speech Date

2025/06/04

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. for the 2025 shareholders' meeting location and related matters

Fact Date

2025-06-04

Describe

1.Date of the board of directors resolution:2025/06/04
2.General shareholders' meeting date:2025/06/25
3.General shareholders' meeting location:
20F Conference room of Guangqi Building, No. 456, Hongcao Rd., Xuhui Dist.,
Shanghai, China
4.Cause for convening the meeting I.Reported matters:None
5.Cause for convening the meeting II.Acknowledged matters:None
6.Cause for convening the meeting III, Matters for Discussion:
(1)Resolutions Regarding the 2024 Board of Directors' Work Report
of the Company
(2)Resolutions Regarding the 2024 Independent Directors' Performance Report
of the Company
(3)Resolutions Regarding the 2024 Supervisory Board's Work Report
of the Company
(4)Resolutions Regarding the 2024 Annual Report and its Summary
of the Company
(5)Resolutions Regarding the 2024 Financial Statements Report
of the Company
(6)Resolutions Regarding the Proposal for the Company's
Director Remuneration Plan for the Year 2025
(7)Resolutions Regarding the Plan for the Guarantee Quota for
the Year 2025 of the Company
(8)Resolutions Regarding the Proposal for the Company's Application for
Credit Line from Banks and Other Financial Institutions
(9)Resolutions Regarding the Proposal for the Completion and Termination
of Certain Fundraising Projects and the Use of Remaining Funds for
Permanent Supplementation of Working Capital
(10)Resolutions Regarding the Proposal to Cancel the Supervisory Board,
Amend the Business Scope, Adjust the Number of Directors and Independent
Directors, Revise the Articles of Incorporation, and Authorize the
Registration of Business Changes
(11)Resolutions Regarding the Proposal to Amend Certain Company Rules and
Regulations
(12)Resolutions Regarding the Proposed for Change Profit Distribution Plan
for the Year 2024
(13)Resolutions Regarding the Proposal for the Nomination of Candidates
for Non-Independent Directors of the Third Board of Directors
(14)Resolutions Regarding the Proposal for the Nomination of Candidates
for Independent Directors of the Third Board of Directors
7.Cause for convening the meeting IV.Election matters:None
8.Cause for convening the meeting V.Other Proposals:None
9.Cause for convening the meeting VI.Extemporary Motions:None
10.Book closure starting date:NA
11.Book closure ending date:NA
12.Any other matters that need to be specified:
For details of the above announcement, please refer to the disclosure website
of Shanghai Stock Exchange: http://www.sse.com.cn/

Speech Date

2025/05/20

Theme

Announcement of the important resolutions of 2025 annual general shareholders’ meeting

Fact Date

2025-05-20

Describe

1.Date of the shareholders' meeting:2025/05/20
2.Important resolutions I.Profit distribution/deficit compensation:
Approved the 2024 earnings distribution
3.Important resolutions II.Amendments of the company charter:
Approved the amendment to the ”Articles of Incorporation”
4.Important resolutions III.Business report and financial statements:
Approved the 2024 annual financial statements and business report
5.Important resolutions IV.Election for directors and supervisors:None
6.Important resolutions V.Other matters:
(1)Approved the amendment to the ”Procedures for Loaning Funds to
Others”
7.Any other matters that need to be specified:None

Speech Date

2025/05/12

Theme

Announcement of the Board of Directors approved the consolidated financial statements for the first quarter of 2025

Fact Date

2025-05-12

Describe

1.Date of the board of directors submitted or approved:2025/05/12
2.Date of the audit committee approved:2025/05/12
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2025/01/01~2025/03/31
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):794,320
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):125,902
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):-53,100
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):-53,286
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):-46,003
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):-30,466
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):-0.39
11.Total assets end of the period (thousand NTD):7,311,355
12.Total liabilities end of the period
(thousand NTD):2,065,463
13.Equity attributable to owners of parent end of the
period (thousand NTD):2,822,842
14.Any other matters that need to be specified:None

Speech Date

2025/05/12

Theme

Announcement pursuant to §22 I subpara. 1 of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies

Fact Date

2025-05-12

Describe

1.Date of occurrence of the event:2025/05/12
2.The public company or its subsidiaries for which
the amount of monetary loans extended to others reaches
20 percent or more of their net worth on the latest
financial statements(1)Name of funding recipient
(2)Relationship with lender(3)Lending limit
(thousand NTD)(4)Outstanding balance (thousand NTD)
up to the date of occurrence(5)Reason for lending
up to the date of occurrence:
(1)Name of funding recipient:Cowealth Medical Tianjin Co., Ltd.
(2)Relationship with lender:
Lender:Coaim Information Technology Co., Ltd.
100% direct and indirect subsidiaries of the parent company
(3)Lending limit (thousand NTD):334,128
(4)Outstanding balance (thousand NTD) up to the date of occurrence:44,189
(5)Reason for lending up to the date of occurrence:working capital
3.The total amount of monetary loans extended to others
as of the date of occurrence:2,625,401
4.The total amount of monetary loans extended to others
as a percentage of the public company’s net worth on
the latest financial statements as of the date of
occurrence:0.93
5.Sources of funds for the company to extend monetary
loans to others:Subsidiary’s own funds
6.Any other matters that need to be specified:None

Speech Date

2025/05/12

Theme

Announcement pursuant to §22 I subpara. 3 of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies

Fact Date

2025-05-12

Describe

1.Date of occurrence of the event:2025/05/12
2.Funding recipient (1)Name(2)Relationship with lender
(3)Lending limit (thousand NTD)(4)Starting outstanding
balance (thousand NTD)(5)New loan (thousand NTD)(6)Is
it part of a scheduled allocation or revolving limit
for the same recipient that the chairman is authorized
by the board of directors to allocate(7)Outstanding
balance (thousand NTD) up to the date of occurrence
(8)Reason for new loan (thousand NTD):
(1)Name:Cowealth Holding Co., Limited
(2)Relationship with lender:
Lender:COWEALTH HOLDING CO.,LTD.
100% direct and indirect subsidiaries of the parent company
(3)Lending limit (thousand NTD):280,164
(4)Starting outstanding balance (thousand NTD):94,382
(5)New loan (thousand NTD):98,877
(6)Is it part of a scheduled allocation or revolving limit for the same
recipient that the chairman is authorized by the board of directors
to allocate:Yes
(7)Outstanding balance (thousand NTD) up to the date of occurrence:193,259
(8)Reason for new loan (thousand NTD):working capital
3.For collaterals provided by the loan recipient, the
(1)Content(2)Value (thousand NTD):
(1)Content:None
(2)Value (thousand NTD):0
4.For the latest financial reports of the loan recipient, the
(1)Capital (thousand NTD)(2)Cumulative gains/losses
(thousand NTD):
(1)Capital (thousand NTD):751,205
(2)Cumulative gains/losses (thousand NTD):1,445,859
5.Method of calculation of interest:
The maximum interest rate on short-term debt from financial institutions
6.For repayment, the(1)Condition(2)Date:
(1)Condition:None
(2)Date:One year starting on the first payment date
7.The amount of monetary loans extended to others as
of the date of occurrence (thousand NTD):1,939,343
8.The total amount of monetary loans extended to others
as a percentage of the public company’s net worth on
the latest financial statements as of the date of
occurrence:0.69
9.Sources of funds for the company to extend monetary
loans to others:Subsidiary’s own funds
10.Any other matters that need to be specified:None

Speech Date

2025/05/12

Theme

Announcement pursuant to §22 I subpara. 3 of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies

Fact Date

2025-05-12

Describe

1.Date of occurrence of the event:2025/05/12
2.Funding recipient (1)Name(2)Relationship with lender
(3)Lending limit (thousand NTD)(4)Starting outstanding
balance (thousand NTD)(5)New loan (thousand NTD)(6)Is
it part of a scheduled allocation or revolving limit
for the same recipient that the chairman is authorized
by the board of directors to allocate(7)Outstanding
balance (thousand NTD) up to the date of occurrence
(8)Reason for new loan (thousand NTD):
(1)Name:Colab Reserch & Development Inc.
(2)Relationship with lender:
Lender:Cowealth Medical China Co., Ltd.
100% direct and indirect subsidiaries of the parent company
(3)Lending limit (thousand NTD):2,149,634
(4)Starting outstanding balance (thousand NTD):0
(5)New loan (thousand NTD):176,756
(6)Is it part of a scheduled allocation or revolving limit for the same
recipient that the chairman is authorized by the board of directors
to allocate:Yes
(7)Outstanding balance (thousand NTD) up to the date of occurrence:176,756
(8)Reason for new loan (thousand NTD):working capital
3.For collaterals provided by the loan recipient, the
(1)Content(2)Value (thousand NTD):
(1)Content:None
(2)Value (thousand NTD):0
4.For the latest financial reports of the loan recipient, the
(1)Capital (thousand NTD)(2)Cumulative gains/losses
(thousand NTD):
(1)Capital (thousand NTD):41,972
(2)Cumulative gains/losses (thousand NTD):17,936
5.Method of calculation of interest:The maximum interest rate
on short-term debt from financial institutions
6.For repayment, the(1)Condition(2)Date:
(1)Condition:None
(2)Date:One year starting on the first payment date
7.The amount of monetary loans extended to others as
of the date of occurrence (thousand NTD):2,625,401
8.The total amount of monetary loans extended to others
as a percentage of the public company’s net worth on
the latest financial statements as of the date of
occurrence:0.93
9.Sources of funds for the company to extend monetary
loans to others:Financial Institutions and Parent company
10.Any other matters that need to be specified:
The original lending limit was due to expire on June 19, 2025.
It has been early repayment and cancelled before the Board of Directors.
This is a new application for a lending limit.

Speech Date

2025/05/12

Theme

Announcement of the board's approval for donation to related party

Fact Date

2025-05-12

Describe

1.Date of occurrence of the event:2025/05/12
2.Reason for the donation:support social welfare
3.Total amount of the donation:NT$200 thousand
4.Counterparty to the donation:Chinese Health&Medical Association
5.Relationship with the company:The chairman and directors of the company
serve as the secretary-general, executive director, and supervisor
6.Name and resume of independent director(s) that expressed
an objection or qualified opinion:None
7.Objection or qualified opinion by the aforementioned
independent director(s):None
8.Any other matters that need to be specified:
The authority for this donation is fully delegated to the chairman to
execute from January 1, 2025 to December 31, 2025.

Speech Date

2025/05/02

Theme

Announcement for the Board of Directors meeting date of 2025Q1 Consolidated Financial Report

Fact Date

2025-05-02

Describe

1.Date of a notice of the board of directors meeting is issued:2025/05/02
2.Expected date of the board of directors meeting is convened:2025/05/12
3.Expected year and quarter of the financial reports
or the annual self-assessed financial information
submitted to the board of directors or approved by
the board of directors:2025Q1 consolidated financial report
4.Any other matters that need to be specified:None

Speech Date

2025/04/29

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. for the resolutions by the Board of Directors

Fact Date

2025-04-29

Describe

1.Date of occurrence of the event:2025/04/29
2.Company name:Cowealth Medical China Co., Ltd(CMC)
3.Relationship to the Company (please enter ”head office” or
”subsidiaries”):subsidiaries
4.Reciprocal shareholding ratios:hold 55.00% shares
5.Cause of occurrence:Announcement on behalf of important subsidiary CMC
for the resolutions by the Board of Directors
1、Resolutions Regarding the 2025 First Quarter Report of the Company
2、Resolutions Regarding the 2024 Annual Sustainability Report of
the Company
6.Countermeasures:None
7.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 9
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):For details of the above announcement,
please refer to the disclosure website of Shanghai Stock Exchange:
http://www.sse.com.cn/

Speech Date

2025/03/25

Theme

Announcement on Behalf of Important Subsidiary CMC Regarding the Cumulative Acquisition of Certificates of Financial Products Reaching the Disclosure Threshold

Fact Date

2025-03-25

Describe

1.Name and nature of the underlying assets (if preferred shares,
the terms and conditions of issuance shall also be indicated,
e.g., dividend yield, etc.):Structured Deposit of Bank of Hangzhou (China)
2.Date of occurrence of the event:2025/02/26~2025/03/25
3.Volume, unit price, and total monetary amount of the transaction:
This purchase is for RMB. 10,000,000
The total cumulative purchase is RMB 35,000,000
4.Trading counterparty and its relationship to the Company
(if the trading counterparty is a natural person and
furthermore is not a related party of the Company, the name
of the trading counterparty is not required to be disclosed):
Bank of Hangzhou (China) (Non-related party)
5.Where the trading counterparty is a related party,
announcement shall also be made of the reason for choosing
the related party as trading counterparty and the
identity of the previous owner, its relationship with
the Company and the trading counterparty, and the previous
date and monetary value of transfer:None
6.Where an owner of the underlying assets within the past
five years has been an related party of the Company, the
announcement shall also include the date and price of
acquisition and disposal by the related party, and its
relationship to the Company at the time of the transaction:None
7.Matters related to the current disposal of creditors’
rights (including types of collaterals of the disposed
creditor’s rights; if creditor’s rights over a related
party, announcement shall be made of the name of the
related party and the book amount of the creditor's
rights, currently being disposed of, over such related
party:None
8.Profit or loss from the disposal (not applicable in
cases of acquisition of securities) (where originally
deferred, the status of recognition shall be listed and
explained):None
9.Terms of delivery or payment (including payment period
and monetary value), restrictive covenants in the contract,
and other important terms and conditions:One-time payment
10.The manner in which the current transaction was
decided, the reference basis for the decision on price,
and the decision-making unit:
Expected Annualized Return of the Product as Announced by the Bank.
Processed according to the company’s approval authority.
11.Net worth per share of the Company’s underlying securities
acquired or disposed of:None
12.Cumulative no.of shares held (including the current
transaction), their monetary value, shareholding percentage,
and status of any restriction of rights (e.g., pledges),
as of the present moment:
Cumulative holding amount:RMB 35,000,000
Restricted rights: RMB 0
13.Ratio of securities investment (including the current
transaction) to the total assets and shareholder’s equity
of the parent company on the latest financial statements,
and the operating capital on the latest financial statements,
as of the present moment:
Percentage of total assets: 2.26%
Percentage of equity of parent company: 5.62%
Working capital: NTD 4,195,291 thousand
14.Broker and broker’s fee:None
15.Concrete purpose or use of the acquisition or disposal:
RMB Structured Deposit
16.Whether the directors expressed any objection to the current
transaction:None
17.Whether the counterparty of the current transaction
is a related party:None
18.Date of the Board of Directors’ resolution:NA
19.Date of ratification by supervisors or approval by
the Audit Committee:NA
20.Whether the CPA issued an opinion on the unreasonableness
regarding the current transaction:None
21.Name of the CPA firm:None
22.Name of the CPA:None
23.License no.of the CPA:None
24.Whether the transaction involved in change of business model:None
25.Details on change of business model:None
26.Details on transactions with the counterparty for the past
year and the expected coming year:Plan according to the overall financial
condition of the group, following the procedures for asset acquisition
or disposal.
27.Source of funds:Operating funds
28.Any other matters that need to be specified:None

Speech Date

2025/03/17

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. to hold 2024 annual performance conference

Fact Date

2025-03-25

Describe

1.Date and time that the Company disclose its financial
or business information to the public:2025/03/25
2.Location that the Company disclose its financial or
business information to the public:Web conference
3.Financial/Business data to be disclosed:
Operating results and financial position for the financial year 2024
4.Content of press release, if provided:NA
5.Any other matters that need to be specified:
Date and time of conference：2025/3/25(February) 11:30-12:30
Online platform：https://www.ir-online.cn
For details of the above announcement, please refer to the disclosure website
of Shanghai Stock Exchange: http://www.sse.com.cn/

Speech Date

2025/03/11

Theme

Announcement of the Board of Directors approved the consolidated financial statements for the year of 2024

Fact Date

2025-03-11

Describe

1.Date of the board of directors submitted or approved:2025/03/11
2.Date of the audit committee approved:2025/03/11
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2024/01/01~2024/12/31
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):4,192,722
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):791,521
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):97,132
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):88,922
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):47,997
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):629
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):0.01
11.Total assets end of the period (thousand NTD):6,958,441
12.Total liabilities end of the period
(thousand NTD):1,764,130
13.Equity attributable to owners of parent end of the
period (thousand NTD):2,798,820
14.Any other matters that need to be specified:None

Speech Date

2025/03/11

Theme

Announcement of Board of Directors' Resolution Not to Distribute Dividends

Fact Date

2025-03-11

Describe

1.Date of the board of directors resolution:2025/03/11
2.Year or quarter which dividends belong to :2024
3.Period which dividends belong to:2024/01/01~2024/12/31
4.Appropriations of earnings in cash dividends to shareholders (NT$
per share):0
5.Cash dividends distributed from legal reserve and capital reserve
to shareholders (NT$ per share):0
6.Total amount of cash dividends to shareholders (NT$):0
7.Appropriations of earnings in stock dividends to shareholders (NT$
per share):0
8.Stock dividends distributed from legal reserve and capital reserve
to shareholders (NT$ per share):0
9.Total amount of stock dividends to shareholders (shares):0
10.Any other matters that need to be specified:None
11.Per value of common stock:NT$10

Speech Date

2025/03/11

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. for the resolutions by the Board of Directors

Fact Date

2025-03-11

Describe

1.Date of occurrence of the event:2025/03/11
2.Company name:Cowealth Medical China Co., Ltd(CMC)
3.Relationship to the Company (please enter ”head office” or
”subsidiaries”):subsidiaries
4.Reciprocal shareholding ratios:hold 55.00% shares
5.Cause of occurrence:Announcement on behalf of important subsidiary CMC
for the resolutions by the Board of Directors
1、Resolutions Regarding the 2024 Annual Report and its Summary
of the Company
2、Resolutions Regarding the 2024 Board of Directors' Work Report
of the Company
3、Resolutions Regarding the 2024 Independent Directors' Performance Report
of the Company
4、Resolutions Regarding the Self-assessment of Independence of
Independent Directors
5、Resolutions Regarding the 2024 General Manager's Work Report
of the Company
6、Resolutions Regarding the 2024 Audit Committee's Performance Report
of the Company
7、Resolutions Regarding the Performance Evaluation Report of the
Accounting Firm for the Year 2024 and the Report on the Supervisory
Duties Performed by the Audit Committee
8、Resolutions Regarding the 2024 Financial Statements Report of the Company
9、Resolutions Regarding the 2024 Internal Control Evaluation Report of the
Company
10、Resolutions Regarding the Special Report on the Utilization of Raised
Funds and its Actual Usage in 2024
11、Resolutions Regarding the termination of certain fundraising projects
and the reallocation of remaining Raised Funds for permanent
supplementation of working capital.
12、Resolutions Regarding the 2025 Audit Plan of the Company
13、Resolutions Regarding the amendment of the remuneration management
system for directors and supervisors.
14、Resolutions Regarding the 2025 Remuneration Plan for the company's
directors of the Company
15、Resolutions Regarding the 2025 Compensation Plan for Senior Management
Personnel of the Company
16、Resolutions Regarding the Proposed Profit Distribution Plan for the
Year 2024
17、Resolutions Regarding the Plan for the Guarantee Quota for the Year 2025
of the Company
18、Resolutions Regarding the company's application for credit facilities
from banks and other financial institutions.
19、Resolutions Regarding the company's use of temporarily idle self-owned
funds for entrusted wealth management.
6.Countermeasures:None
7.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 9
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):For details of the above announcement,
please refer to the disclosure website of Shanghai Stock Exchange:
http://www.sse.com.cn/

Speech Date

2025/03/11

Theme

Announcement on behalf of important subsidiary Cowealth Medical China Co., Ltd. for the resolution by the Board of Directors to distribute dividends

Fact Date

2025-03-11

Describe

1.Date of the board of directors resolution:2025/03/11
2.Type and monetary amount of dividend distribution:
Cash Dividends RMB$ 19,902,631.65(tax included)
3.Any other matters that need to be specified:
For details of the above announcement, please refer to the disclosure website
of Shanghai Stock Exchange: http://www.sse.com.cn/

Speech Date

2025/03/05

Theme

Announcement of the board's approval for donation to related party

Fact Date

2025-03-05

Describe

1.Date of occurrence of the event:2025/03/05
2.Reason for the donation:Support for Social Welfare
3.Total amount of the donation:NT$60 thousand
4.Counterparty to the donation:Association for Contemporary
Medicine and Management (ACMM)
5.Relationship with the company:The Chairman of the Company
serves as its Honorary Secretary-General
6.Name and resume of independent director(s) that expressed
an objection or qualified opinion:None
7.Objection or qualified opinion by the aforementioned
independent director(s):None
8.Any other matters that need to be specified:
The authority for this donation is fully delegated to the chairman to
execute from January 1, 2025 to December 31, 2025.

Speech Date

2025/03/05

Theme

Board of Directors resolved to convene the 2025 Annual General Shareholders’Meeting

Fact Date

2025-03-05

Describe

1.Date of the board of directors resolution:2025/03/05
2.General shareholders' meeting date:2025/05/20
3.General shareholders' meeting location:Cowealth Center of 23F, No. 76,
Sec. 2, Dunhua S. Rd., Da’an Dist., Taipei City 106485, Taiwan (R.O.C.)
4.Shareholders meeting will be held by means of (physical shareholders
meeting/ visual communication assisted shareholders meeting /
visual communication shareholders meeting):physical shareholders meeting
5.Cause for convening the meeting I.Reported matters:
(1)2024 annual business report
(2)Audit Committee's review of the 2024 annual final accounting books
and statements
(3)Report on 2024 employees' and directors' remuneration
(4)Report on 2024 director compensation
6.Cause for convening the meeting II.Acknowledged matters:
(1)2024 annual financial statements and business report
(2)2024 earnings distribution
7.Cause for convening the meeting III.Matters for Discussion:
(1)Amendments to the ”Articles of Association”
(2)Amendments to the ”Procedures for Loaning of Funds to Others”
8.Cause for convening the meeting IV.Election matters:None
9.Cause for convening the meeting V.Other Proposals:None
10.Cause for convening the meeting VI.Extemporary Motions:None
11.Book closure starting date:2025/03/22
12.Book closure ending date:2025/05/20
13.Any other matters that need to be specified:
In accordance with the laws of the Republic of China, the following matters
related to the acceptance of shareholder proposals in writing are
established:
(1)Acceptance period: from March 7, 2025 to March 17, 2025.
(2)Acceptance location:23F, No. 76, Sec. 2, Dunhua S. Rd., Da’an Dist.,
Taipei City 106485, Taiwan (R.O.C.)
(3) Acceptance Location: Taiwan Branch of Allied Healthcare Medical
Equipment Co., Ltd., a company incorporated in the Cayman Islands.
(4) Proposal Eligibility: Shareholders who hold more than 1%
of the total issued shares (whether individually or collectively).
(5) Proposal Method: Proposals must be submitted in writing and limited to
one proposal per shareholder. If more than one proposal is submitted,
none will be considered. Proposals submitted by shareholders are limited to
300 words.Proposals exceeding 300 words will not be included in the agenda.
(6) Other Matters Related to Shareholder Proposals: Any matters not covered
regarding shareholder proposals will be handled according to relevant laws
and regulations. Whether or not a proposal will be excluded from the agenda
according to the company’s articles of association will be reviewed by
the board of directors after the proposal acceptance period has ended.
The detailed content of the accepted proposals will be based on the
company’s public announcements on the MOPS.
For this shareholder meeting, shareholders will exercise their voting rights
electronically. Relevant details are as follows:
(1) Voting Period: From April 20, 2025, to May 17, 2025.
(2) Electronic Voting Platform: Taiwan Depository & Clearing Corporation,
website: https://www.stockvote.com.tw

Speech Date

2025/03/05

Theme

Announcement pursuant to §22 I subpara. 1 of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies

Fact Date

2025-03-05

Describe

1.Date of occurrence of the event:2025/03/05
2.The public company or its subsidiaries for which
the amount of monetary loans extended to others reaches
20 percent or more of their net worth on the latest
financial statements(1)Name of funding recipient
(2)Relationship with lender(3)Lending limit
(thousand NTD)(4)Outstanding balance (thousand NTD)
up to the date of occurrence(5)Reason for lending
up to the date of occurrence:
(1)Name of funding recipient:Cowealth Medical Tianjin Co., Ltd.
(2)Relationship with lender:
Lender: Cowealth Medical China Co., Ltd.
100% direct and indirect subsidiaries of the company
(3)Lending limit (thousand NTD):2,106,410
(4)Outstanding balance (thousand NTD) up to the date of occurrence:2,246
(5)Reason for lending up to the date of occurrence:Operating Capital
3.The total amount of monetary loans extended to others
as of the date of occurrence:2,682,547
4.The total amount of monetary loans extended to others
as a percentage of the public company’s net worth on
the latest financial statements as of the date of
occurrence:0.96
5.Sources of funds for the company to extend monetary
loans to others:Subsidiary’s own funds and Financial institutions
6.Any other matters that need to be specified:None

Speech Date

2025/03/03

Theme

Announcement of the Board of Directors meeting date for the Consolidated Financial Report for the year of 2024

Fact Date

2025-03-03

Describe

1.Date of a notice of the board of directors meeting is issued:2025/03/03
2.Expected date of the board of directors meeting is convened:2025/03/11
3.Expected year and quarter of the financial reports
or the annual self-assessed financial information
submitted to the board of directors or approved by
the board of directors:The Consolidated Financial Report for the year of 2024
4.Any other matters that need to be specified:None

Speech Date

2025/02/07

Theme

Announcement on Behalf of Important Subsidiary CMC Regarding the Cumulative Acquisition of Certificates of Deposit Reaching the Disclosure Threshold

Fact Date

2025-02-07

Describe

1.Name and nature of the underlying assets (if preferred shares,
the terms and conditions of issuance shall also be indicated,
e.g., dividend yield, etc.):Certificates of deposit of Fubon Bank (China)
2.Date of occurrence of the event:2025/02/07~2025/02/07
3.Volume, unit price, and total monetary amount of the transaction:
RMB 42,719,166.68
4.Trading counterparty and its relationship to the Company
(if the trading counterparty is a natural person and
furthermore is not a related party of the Company, the name
of the trading counterparty is not required to be disclosed):
Fubon Bank (China) (Non-related party)
5.Where the trading counterparty is a related party,
announcement shall also be made of the reason for choosing
the related party as trading counterparty and the
identity of the previous owner, its relationship with
the Company and the trading counterparty, and the previous
date and monetary value of transfer:None
6.Where an owner of the underlying assets within the past
five years has been an related party of the Company, the
announcement shall also include the date and price of
acquisition and disposal by the related party, and its
relationship to the Company at the time of the transaction:None
7.Matters related to the current disposal of creditors’
rights (including types of collaterals of the disposed
creditor’s rights; if creditor’s rights over a related
party, announcement shall be made of the name of the
related party and the book amount of the creditor's
rights, currently being disposed of, over such related
party:None
8.Profit or loss from the disposal (not applicable in
cases of acquisition of securities) (where originally
deferred, the status of recognition shall be listed and
explained):None
9.Terms of delivery or payment (including payment period
and monetary value), restrictive covenants in the contract,
and other important terms and conditions:Interest payment upon maturity
10.The manner in which the current transaction was
decided, the reference basis for the decision on price,
and the decision-making unit:
Processed according to the company’s approval authority.
11.Net worth per share of the Company’s underlying securities
acquired or disposed of:None
12.Cumulative no.of shares held (including the current
transaction), their monetary value, shareholding percentage,
and status of any restriction of rights (e.g., pledges),
as of the present moment:
Cumulative holding amount: RMB 42,719,166.68
Restricted rights: RMB 0
13.Ratio of securities investment (including the current
transaction) to the total assets and shareholder’s equity
of the parent company on the latest financial statements,
and the operating capital on the latest financial statements,
as of the present moment:
Percentage of total assets: 2.81%.
Percentage of equity of parent company: 6.87%.
Working capital: NTD 4,139,205,000
14.Broker and broker’s fee:None
15.Concrete purpose or use of the acquisition or disposal:
RMB certificates of deposit
16.Whether the directors expressed any objection to the current
transaction:None
17.Whether the counterparty of the current transaction
is a related party:No
18.Date of the Board of Directors’ resolution:NA
19.Date of ratification by supervisors or approval by
the Audit Committee:NA
20.Whether the CPA issued an opinion on the unreasonableness
regarding the current transaction:None
21.Name of the CPA firm:None
22.Name of the CPA:None
23.License no.of the CPA:None
24.Whether the transaction involved in change of business model:No
25.Details on change of business model:None
26.Details on transactions with the counterparty for the past
year and the expected coming year:Plan according to the overall financial
condition of the group, following the procedures for asset acquisition
or disposal.
27.Source of funds:Operating funds
28.Any other matters that need to be specified:None

Speech Date

2025/01/14

Theme

Announcement of the Board of Directors approved the change of Financial Officer, Accounting Officer and Acting Spokesperson

Fact Date

2025-01-14

Describe

1.Type of personnel changed (please enter:
spokesperson, acting spokesperson, important
personnel (CEO, COO, CMO, CSO, etc.), financial
officer, accounting officer, corporate governance
officer, chief information security officer,research
and development officer, internal audit officer, or
designated and non-designated representatives):
Financial Officer, Accounting Officer and Acting Spokesperson
2.Date of occurrence of the change:2025/01/14
3.Name, title, and resume of the previous position holder:
(1) Financial Officer: Gao, Heng-Zheng / Accounting Manager (acting)
(2) Accounting Officer: Gao, Heng-Zheng / Accounting Manager (acting)
(3) Acting Spokesperson: Ma, Fang / Internal Audit Officer (acting)
4.Name, title, and resume of the new position holder:
(1) Financial Officer: Tian, Jing/ Finance Director
(2) Accounting Officer: Tian, Jing / Finance Director
(3) Acting Spokesperson: Ma, Fang / Internal Audit Officer
5.Type of change (please enter: ”resignation”,
”position adjustment”, ”dismissal”, ”retirement”,
”death” or ”new replacement”):New replacement
6.Reason for the change:New replacement
7.Effective date:2025/01/14
8.Any other matters that need to be specified:
The newly appointed individuals were approved for appointment by
the Board of Directors on January 14, 2025.

Speech Date

2025/01/14

Theme

Announcement pursuant to §22 I subpara. 3 of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies

Fact Date

2025-01-14

Describe

1.Date of occurrence of the event:2025/01/14
2.Funding recipient (1)Name(2)Relationship with lender
(3)Lending limit (thousand NTD)(4)Starting outstanding
balance (thousand NTD)(5)New loan (thousand NTD)(6)Is
it part of a scheduled allocation or revolving limit
for the same recipient that the chairman is authorized
by the board of directors to allocate(7)Outstanding
balance (thousand NTD) up to the date of occurrence
(8)Reason for new loan (thousand NTD):
(1)Name:Royal Seal Holding Co., Ltd.
(2)Relationship with lender:
Lender:Cowealth Medical China Co., Ltd.
The company's subsidiaries directly and indirectly hold 100% of the shares
(3)Lending limit (thousand NTD):2,106,410
(4)Starting outstanding balance (thousand NTD):179,452
(5)New loan (thousand NTD):717,808
(6)Is it part of a scheduled allocation or revolving limit for the same
recipient that the chairman is authorized by the board of directors
to allocate:Yes
(7)Outstanding balance (thousand NTD) up to the date of occurrence:897,260
(8)Reason for new loan (thousand NTD):working capital
3.For collaterals provided by the loan recipient, the
(1)Content(2)Value (thousand NTD):
(1)Content:None
(2)Value (thousand NTD):0
4.For the latest financial reports of the loan recipient, the
(1)Capital (thousand NTD)(2)Cumulative gains/losses
(thousand NTD):
(1)Capital (thousand NTD):707,751
(2)Cumulative gains/losses (thousand NTD):-135,356
5.Method of calculation of interest:
The maximum interest rate on short-term debt from financial institutions
6.For repayment, the(1)Condition(2)Date:
(1)Condition:None
(2)Date:One year starting on the first payment date
7.The amount of monetary loans extended to others as
of the date of occurrence (thousand NTD):2,606,077
8.The total amount of monetary loans extended to others
as a percentage of the public company’s net worth on
the latest financial statements as of the date of
occurrence:0.93
9.Sources of funds for the company to extend monetary
loans to others:Financial institutions and parent company
10.Any other matters that need to be specified:None